Infliximab as an Effective Second-Line Treatment for IVIG-Resistant Kawasaki Disease Accompanied by Severe Dyslipidemia - Poll - MDSpire

Infliximab as an Effective Second-Line Treatment for IVIG-Resistant Kawasaki Disease Accompanied by Severe Dyslipidemia

  • By

  • Yuto Sunaga

  • Yohei Hasebe

  • Masashi Yoshizawa

  • Yosuke Kono

  • Keiichi Koizumi

  • Nobuyuki Katsumata

  • Takako Toda

  • Minako Hoshiai

  • Koji Kobayashi

  • Sho Hokibara

  • Hiroko Oshiro

  • Emi Sawanobori

  • Tomoaki Sano

  • Masanori Ohta

  • Makoto Tsuruta

  • Makoto Nakamura

  • Kazumasa Sato

  • Hiroki Sato

  • Takeshi Inukai

  • June 4, 2026

  • 0 min

Share

Original Source(s)

Infliximab as an Effective Second-Line Treatment for IVIG-Resistant Kawasaki Disease Accompanied by Severe Dyslipidemia

  • by Yuto Sunaga, Yohei Hasebe, Masashi Yoshizawa, Yosuke Kono, Keiichi Koizumi, Nobuyuki Katsumata, Takako Toda, Minako Hoshiai, Koji Kobayashi, Sho Hokibara, Hiroko Oshiro, Emi Sawanobori, Tomoaki Sano, Masanori Ohta, Makoto Tsuruta, Makoto Nakamura, Kazumasa Sato, Hiroki Sato, Takeshi Inukai

  • June 4, 2026

Related Content

Real-world effectiveness and safety of dupilumab therapy in children ≤6 years with uncontrolled persistent asthma: a propensity-matched retrospective cohort study

Correction: Clinical utility of a host-protein test for suspected infection in the pediatric emergency department: a pragmatic pre-/post-implementation study

Case Report: Reversible myelodysplastic syndrome secondary to sodium valproate in an epileptic child